Panel Discussion: The new innovation economy: Building the ecosystem behind the molecule

Panellists in this video: • Dr Maneesh Paul. S.; M.Sc., Ph.D., FIDSA; CEO, Microvioma (MODERATOR) • Ms Kavitha Iyer Rodrigues, Founder & CEO, Zumutor Biologics • Dr Anandkrishna Kulkarni, VP & Head-Global Program Office and Operational Excellence, Syngene International • Dr M.S. Vijaykanth, M.Pharm, Ph.D., Sr VP and Head R&D Formulations, OneSource Specialty Pharma • Dr Mohamed Adil, MD, Bangalore Bioinnovation Centre • Dr Rakesh Kumar Bhasin, Head GF R&D, Biocon Pharma • Dr Huzaifa S Choonia, AVP and Head, Drug Substance MSAT, OneSource Specialty Pharma • Dr Shailendra Gaur, Director, Process Science, Aspergen Inc (Cipla and Kemwell’s JV) Key Highlights: [1] Strong programme governance is critical to accelerate innovation, enabling clear accountability, structured risk assessment and faster go/no-go decisions at different stages of drug development. [2] Startups need to be treated as innovation engines rather than small pharma companies, with CROs and CDMOs providing the expertise, platforms and regulatory support needed to move molecules forward [3] The biggest gaps in transferring a molecule to a medicine lie in development ability, scalability, regulatory strategy and IP protection, all of which need to be addressed early and in parallel [4] Technology transfer must go beyond product performance to ensure commercial reproducibility, with robust process controls, critical process parameters and analytical requirements built into the development process [5] A common technology-transfer framework can improve handoffs across the pharma ecosystem, but it must combine a standard core information set with modality-specific requirements for small molecules, biologics, biosimilars and cell therapies [6] The future competitive advantage will increasingly depend on how efficiently knowledge and data are preserved and transferred, rather than simply on who discovers a molecule first [7] Standardisation should focus on the architecture and format, not the science, as each molecule, formulation and process is distinct and requires flexibility based on its development stage and modality [8] India needs a more integrated and dynamic innovation ecosystem, bringing together academia, startups, CROs, CDMOs and pharma companies to establish consistent processes while creating room for emerging technologies and new modalities. The post Panel Discussion: The new innovation economy: Building the ecosystem behind the molecule appeared first on Express Pharma.